Ariad is a pharmaceutical company that works to treat leukemia patients. It recently released a drug that was previously taken off the market, but is now back on the shelves called Inclusig. Many shareholder are anticipating a Buy Out sometime this year. I grew some confidence in this stock and plan to jump back in if it hits $6.66 again. For some reason, this stock has a magnet at 6.66 and I believe we will eventually be back to this resistence point once the rumors of a buy out have settled and people start to take profits.